-
From January to March 2022, CDE will undertake to accept 18 new Chinese medicine registration applications
Time of Update: 2022-04-15
From January to March 2022, the company has received a total of 5 new Chinese medicine registration applications, including 2.
This is also the first innovative traditional Chinese medicine drug approved for marketing in China this year .
-
Under the normalization of alliance procurement, a large number of drugs and consumables will be reduced in price
Time of Update: 2022-04-15
Recently, the Inner Mongolia Autonomous Region Pharmaceutical Procurement Center issued the "Notice on Publicizing the Results of the Proposed Selection of the Third Batch of Centralized Procurement of Drugs in the "Eight Provinces and Two Regions" Inter-Provincial Alliance" .
-
In the first quarter of 2022, companies in the field of biological products performed well
Time of Update: 2022-04-15
For example, Tonghua Dongbao, an "insulin leader", expects to achieve a net profit of 817 million yuan attributable to shareholders of listed companies in the first quarter of 2022, an increase of 480 million yuan over the same period last year, or an increase of about 142.
-
Under the normalization of centralized procurement, a large number of pharmaceutical companies have accelerated the consistency evaluation!
Time of Update: 2022-04-15
Tianyao announced on the evening of March 22 that the dexamethasone sodium phosphate injection of its subsidiary Jinyao Pharmaceutical passed the quality and efficacy consistency evaluation of generic drugs .
-
All localities are vigorously promoting the innovative development of the biomedical industry and striding forward to the "100 billion-level" market!
Time of Update: 2022-04-15
According to the "14th Five-Year Plan for Hefei's Biomedical Industry Development Plan", by 2025, the output value of the city's biomedical industry will exceed 100 billion yuan, and strive to build a national strategic emerging industry cluster .
-
A large number of drugs for the treatment of advanced solid tumors have been approved for clinical use, involving Hengrui, Henlius, etc.
Time of Update: 2022-04-15
HLX301 Fosun Pharma announced that recently, the application for clinical trials of HLX301 (recombinant human anti-PD-L1 and anti-TIGIT bispecific antibody injection) of Henlius, a holding subsidiary of the company, for the treatment of advanced tumors has been approved by the State Food and Drug Administration.
-
In March, 86 new varieties passed the consistency evaluation, and this pharmaceutical company has 5 varieties that have passed the evaluation.
Time of Update: 2022-04-15
In March, 5 varieties have passed the consistency evaluation, including salbutamol desulfate injection, dexamethasone sodium phosphate injection, lidocaine hydrochloride injection, Laxole sustained-release tablets, etc.
com, the market size of terminal salbutamol in China's public medical institutions has exceeded 1 billion yuan in 2020, of which injection sales accounted for about 21% .
-
Over 300 companies have received institutional attention!
Time of Update: 2022-04-15
Institutions mainly focus on the company's views on DRG/DIP, the current competitive landscape of developing countries, how the company can ensure the long-term growth of developing countries in the future, and the progress of medical treatment in overseas markets .
-
The 3rd CBIC Cell Bio-Industry Conference and Biomedicine Conference
Time of Update: 2022-04-15
[Pharmaceutical Network Conference Forum] The biopharmaceutical industry is one of the key strategic emerging industries in China. At present, China is in an important stage of strategic transformat
-
In the past 5 days, this pharmaceutical stock has been investigated by more than 60 institutions, with a net inflow of over 100 million
Time of Update: 2022-04-15
In the communication and interaction session, the agency mainly focused on the company's business development, the reasons for the increase in performance, the number of orders in hand, the impact of traditional Chinese medicine policies on the company's business, the current situation of Shaoxing's CDMO and future plans .
-
In the context of soil census, the seminar on prevention and detection of heavy metal pollution in agricultural land invites you to have an online dialogue on March 17
Time of Update: 2022-04-15
Symposium on Prevention and Detection of Heavy Metal Pollution in Agricultural Land "Lights Up" Soil census, as an important survey of national conditions and national strength, is inseparable from the support of professional technology and equipment .
-
The 3rd QbD Biopharmaceutical Quality Science Conference
Time of Update: 2022-04-15
In this context, how local pharmaceutical companies can go overseas on the premise of adhering to drug quality standards is the focus of this conference .
-
Within 1 day, 3 pharmaceutical companies reported their annual results!
Time of Update: 2022-04-15
The net profit attributable to shareholders of the listed company was 465 million yuan, a year-on-year increase of 10.
28% year-on-year According to the 2021 annual report disclosed by Fosun Pharma, the company achieved operating income of 39.
-
The research and development of ALK inhibitors is booming, and domestic and foreign pharmaceutical companies such as Takeda and Betta Pharmaceuticals have deployed
Time of Update: 2022-04-15
Among them, crizotinib launched by Pfizer is the first ALK tyrosine kinase inhibitor launched in the world, bringing a new treatment option for ALK-positive advanced non-small cell lung cancer .
-
More than 5,000 drugs have been reduced in price!
Time of Update: 2022-04-15
[Pharmaceutical Network Industry News] According to the 2021 Annual Monitoring Circular of the Provincial Pharmaceutical Recruitment and Procurement Price Guidance Mechanism issued by the Hainan Provincial Medical Insurance Bureau on March 17, 5,049 varieties of drugs were received by enterprises to reduce their prices, with an average decrease of 31.
-
After the second IPO, the pharmaceutical company finally landed on the GEM today!
Time of Update: 2022-04-15
According to public information, Fujilai is mainly engaged in the research and development, production and sales of pharmaceutical intermediates, APIs and raw materials for health care products.
-
Domestic new drugs are "going overseas" constantly, and the value of innovation is accelerating
Time of Update: 2022-04-15
A few days ago, Jinfang Pharmaceutical announced that it has reached a cooperation with SELLAS Life Sciences Group of the United States to license the global development and commercialization rights of the highly selective CDK9 inhibitor GFH009 outside the Greater China region (including mainland China, Hong Kong, Macau, and Taiwan) to SELLAS.
-
CXO continues to develop well, and the performance of leading companies has risen sharply
Time of Update: 2022-04-15
[Pharmaceutical Network Industry News] In recent years, with the continuous transfer of global innovative drug outsourcing services to emerging Asian markets such as China, and the continuous complexity and refinement of the industrial chain of new drug R&D and production, the cost and the difficulty of R&D have increased.
By 2025, the market for new drug R&D outsourcing services may reach $244 billion .
-
Pharmaceutical companies are scrambling to develop Class 1 new drugs, and new progress continues!
Time of Update: 2022-04-15
Luye Pharma's Class 1 New Drug Under Development Approved for Phase III Clinical Trials Recently, Luye Pharma announced that the group's new product under development (NCE) and China's Class 1 new chemical drug "LY03005" has been approved by the Center for Drug Evaluation of the State Drug Administration of China (CDE) approved a Phase III clinical trial for the treatment of generalized anxiety disorder .
-
The prevalence of diabetes continues to rise, and traditional Chinese medicine is included in the national diabetes prevention and control guidelines
Time of Update: 2022-04-15
For the first time, the "Guidelines" added the "Traditional Chinese Medicine Prevention and Treatment of Diabetes" chapter to actively support and encourage the integration of traditional Chinese medicine into diabetes comprehensive The prevention and treatment system should give full play to the advantages of holistic view and syndrome differentiation, combined with physical constitution identification, etc.
